Table 1 Characteristics of 27 studies included
Study (Year) (Ref.) | Country | No. of Male (%) | Age, Yearsa | No. of HBeAg positivity (%) | No. of cirrhosis (%) | Treatments | Median Treatment Duration | Person-years | HCC Cases | Sample size | Study Scored |
|---|---|---|---|---|---|---|---|---|---|---|---|
Choi, J. 2019( [21]) Nationalwide cohort | South Korea | 6802 (62) | 49.1 ± 9.8 | NA | 2891 (26) | ETV | 4.25 | 52,991 | 567 | 10,923 | 7 |
6834 (63) | 49.0 ± 9.8 | NA | 2919 (27) | TDF | 3.00 | 53,030 | 350 | 10,923 | |||
Coffin, C. S. 2014 ( [22])b | Canada | 209 (65) | 46 (38–55) | 103 (32) | 63 (20) | ETV | 3.20 | 407 | 1 | 127 | 6 |
TDF | 3.20 | 423 | 3 | 132 | |||||||
Other NAs | 3.20 | 203 | 7 | 63 | |||||||
Güzelbulut, F. 2021 ( [23]) | Turkey | 186(72) | 46.01 ± 14.06 | 53(21) | 95(37) | ETV | 4.68 | 1203 | 17 | 257 | 6 |
234(60) | 43.81 ± 13.40 | 102(26) | 85(22) | TDF | 3.54 | 1379 | 9 | 390 | |||
Ha, I. 2020 ( [24]) | South Korea | 181 (61) | 48 ± 16 | 161 (54) | 39 (13) | ETV | 3.00 | 894 | 11 | 298 | 8 |
179 (60) | 48 ± 14 | 174 (58) | 39 (13) | TDF | 3.00 | 894 | 22 | 298 | |||
Hosaka, T. 2013 ( [25]) | Japan | 210 (66) | 46 ± 12.1 | 135 (43) | 79 (25) | ETV | 3.30 | 1064 | 6 | 316 | 8 |
210 (66) | 46 ± 13.5 | 133 (42) | 85 (27) | Control | 7.60 | 2978 | 72 | 316 | |||
136 (75) | 45 ± 10.7 | 71 (39) | 85 (47) | Other NAs | 6.80 | 1267 | 19 | 182 | |||
Hsu, Y. C. 2018 ( [26])b | China | 282 (73) | 46 (36-55) | 158 (41) | 195 (51) | ETV | 6.06 | 1357 | 20 | 224 | 6 |
TDF | 6.06 | 127 | 0 | 21 | |||||||
Other NAs | 6.06 | 842 | 16 | 139 | |||||||
Hsu, Y. C. 2020 ( [27]) | China, Japan, South Korea, USA, | 354(68) | 44.12 ± 0.54 | 187(36) | 107(21) | ETV | 5.00 | 2600 | 19 | 520 | 8 |
338(65) | 44.88 ± 0.55 | 177(34) | 105(20) | TDF | 3.24 | 1685 | 11 | 520 | |||
Kim, D. S. 2018 ( [28])b | South Korea | 210 (63) | 51.0 (42.8-57.0) | 172 (51) | 164 (49) | ETV | 3.92 | 165 | 3 | 42 | 6 |
TDF | 3.06 | 894 | 22 | 292 | |||||||
Kim, E. J. 2017 ( [29]) | South Korea | 366 (63) | 51 ± 9 | 303 (52) | 578 (100) | ETV | 3.58 | 2069 | 81 | 578 | 5 |
Kim, G. A. 2017 ( [30]) | South Korea | 1288 (64) | 47 ± 11 | 1168 (58) | 815 (41) | ETV | 4.82 | 9640 | 228 | 2000 | 5 |
Kim, J. H. 2017 ( [31]) | South Korea | 564 (64) | 47.7 ± 10.7 | 483 (55) | 443 (51) | ETV | 4.50 | 3938 | 85 | 875 | 5 |
Kim, S. U. 2019 ( [32]) | South Korea | 793 (62) | 48.6 ± 11.4 | 640 (50) | 394 (31) | ETV | 5.62 | 6187 | 93 | 1278 | 8 |
794 (62) | 48.2 ± 12.0 | 640 (50) | 400 (31) | TDF | 4.72 | 5457 | 91 | 1278 | |||
Lee, J. 2016 ( [33]) | South Korea | 67 (66) | 46.4 ± 11.2 | 71 (70) | 36 (35) | ETV | 3.17 | 323 | 7 | 102 | 5 |
Lee, S. W. 2019 ( [12]) | South Korea | 806 (59) | 46.96 ± 11.75 | 814 (59) | 465 (34) | ETV | 5.00 | 6850 | 64 | 1370 | 8 |
798 (58) | 46.92 ± 11.13 | 807 (59) | 464 (34) | TDF | 3.03 | 4151 | 47 | 1370 | |||
Li, L. 2012 ( [34]) | China | 29 (76) | 54.7 ± 11.8 | 23 (61) | 38 (100) | ETV | 2.00 | 76 | 0 | 38 | 6 |
24 (62) | 52.2 ± 10.8 | NA | 39 (100) | Control | 2.00 | 78 | 4 | 39 | |||
80 (69) | 50.1 | 74 (64) | 116 (100) | Other NAs | 2.00 | 232 | 14 | 116 | |||
Li, Y. 2013 ( [35]) | China | 14 (56) | 36.32 ± 10.50 | 25 (100) | NA | ETV | 5.00 | 125 | 3 | 25 | 6 |
12 (52) | 32.10 ± 0.21 | 23 (100) | NA | Other NAs | 5.00 | 115 | 3 | 23 | |||
Lim, Y. S. 2014 ( [36]) | South Korea | 1193 (67) | 46.1 ± 10.1 | 1133 (63) | 933 (52) | ETV | 3.17 | 5687 | 137 | 1792 | 9 |
1179 (66) | 46.1 ± 10.9 | 1107 (62) | 934 (52) | Other NAs | 5.30 | 9503 | 234 | 1792 | |||
Lin, T. C. 2018 ( [37]) | China | NA | NA | NA | NA | ETV | 5.24 | 938 | 13 | 179 | 5 |
Oh, H. 2020 ( [38]) | South Korea | 319(62) | 49.2 ± 12.6 | 314(61) | 238(46) | ETV | 4.70 | 2425 | 29 | 516 | 8 |
325(63) | 49.0 ± 9.4 | 311(60) | 224(43) | TDF | 4.80 | 2477 | 37 | 516 | |||
Ouyang, Y. 2011 ( [39]) | China | 22 (88) | 50.1 ± 11.6 | 25 (100) | 25 (100) | ETV | 0.92 | 23 | 2 | 25 | 7 |
78 (74) | 46 | 105 (100) | 105 (100) | Other NAs | 0.92 | 97 | 9 | 105 | |||
Sou, F. M. 2020 ( [40]) | China | 1018(73) | 50 ± 17 | 491(35) | 507(36) | ETV | 7.29 | 10,190 | 133 | 1397 | 5 |
Shin, J. W. 2020 ( [41]) | South Korea | 365(62) | 50 ± 11 | 365(62) | 276(47) | ETV | 4.86 | 2860 | 40 | 589 | 8 |
358(61) | 50 ± 11 | 354(60) | 282(48) | TDF | 3.58 | 2110 | 23 | 589 | |||
Sohn, W. 2017 ( [42]) Testing cohort | South Korea | 641 (65) | 47.4 ± 10.5 | 556 (56) | 389 (39) | ETV | 2.10 | 2079 | 58 | 990 | 5 |
Sohn, W. 2017 ( [42]) Validation cohort | South Korea | 669 (62) | 46.6 ± 11.5 | 658 (61) | 376 (35) | ETV | 3.50 | 3749 | 85 | 1071 | 5 |
Su, T. H. 2016 ( [43]) | China | 345 (77) | 50 (44-58) | 150 (33) | 450 (100) | ETV | 4.00 | 1782 | 31 | 450 | 7 |
345 (77) | 51 (43-59) | 131 (29) | 450 (100) | Control | 6.00 | 3021 | 115 | 450 | |||
Wu, I. T. 2017 ( [44]) | China | 230 (73) | 47 ± 12.3 | 172 (55) | 94 (30) | ETV | 4.08 | 1277 | 21 | 313 | 7 |
74 (70) | 47.1 ± 12.1 | 50 (47) | 29 (27) | TDF | 3.16 | 335 | 8 | 106 | |||
Yip, T. C. 2020 ( [45]) | China | 2267 (49) | 42.9 ± 12.7 | 2480 (53) | 167 (4) | ETV | 2.90 | 13,444 | 70 | 4636 | 8 |
587 (49) | 44.4 ± 13.1 | 625 (52) | 37 (3) | TDF | 2.80 | 3360 | 7 | 1200 | |||
Yu, J. H. 2018 ( [46]) | South Korea | 272 (67) | 53 (18–84) | 212 (52) | 148 (36) | ETV | 5.83 | 2367 | 31 | 406 | 6 |
104 (59) | 49 (20–84) | 104 (59) | 77 (44) | TDF | 2.80 | 493 | 7 | 176 |